These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32572467)

  • 1. Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
    Zuily S; de Laat B; Guillemin F; Kelchtermans H; Magy-Bertrand N; Desmurs-Clavel H; Lambert M; Poindron V; de Maistre E; Dufrost V; Risse J; Shums Z; Norman GL; de Groot PG; Lacolley P; Lecompte T; Regnault V; Wahl D
    J Appl Lab Med; 2020 Nov; 5(6):1242-1252. PubMed ID: 32572467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
    Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
    Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
    de Laat B; Eckmann CM; van Schagen M; Meijer AB; Mertens K; van Mourik JA
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):757-64. PubMed ID: 19002041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
    Nojima J; Kuratsune H; Suehisa E; Iwatani Y; Kanakura Y
    Clin Chem; 2005 Mar; 51(3):545-52. PubMed ID: 15637132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β
    Nakamura H; Oku K; Amengual O; Ohmura K; Fujieda Y; Kato M; Bohgaki T; Yasuda S; Atsumi T
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):627-634. PubMed ID: 28686816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
    Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
    J Thromb Haemost; 2014 Nov; 12(11):1801-9. PubMed ID: 25196808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives.
    Foret T; Dufrost V; Lagrange J; Costa P; Mourey G; Lecompte T; Magy-Bertrand N; Regnault V; Zuily S; Wahl D
    Curr Rheumatol Rep; 2024 May; 26(5):178-187. PubMed ID: 38372872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.
    Wahl D; Membre A; Perret-Guillaume C; Regnault V; Lecompte T
    Curr Rheumatol Rep; 2009 Feb; 11(1):77-81. PubMed ID: 19171115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
    Chen J; Sun S; Yan Q; Bao C; Fu Q
    Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis.
    Pericleous C; Ruiz-Limón P; Romay-Penabad Z; Marín AC; Garza-Garcia A; Murfitt L; Driscoll PC; Latchman DS; Isenberg DA; Giles I; Ioannou Y; Rahman A; Pierangeli SS
    Rheumatology (Oxford); 2015 Apr; 54(4):722-7. PubMed ID: 25273993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.
    Pericleous C; Ferreira I; Borghi O; Pregnolato F; McDonnell T; Garza-Garcia A; Driscoll P; Pierangeli S; Isenberg D; Ioannou Y; Giles I; Meroni PL; Rahman A
    PLoS One; 2016; 11(6):e0156407. PubMed ID: 27253369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
    Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
    J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome.
    Montalvão S; Elídio PS; da Silva Saraiva S; de Moraes Mazetto B; Colella MP; de Paula EV; Appenzeller S; Annichino-Bizzacchi J; Orsi FA
    Thromb Res; 2016 Dec; 148():32-37. PubMed ID: 27770664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study.
    Saccone G; Berghella V; Maruotti GM; Ghi T; Rizzo G; Simonazzi G; Rizzo N; Facchinetti F; Dall'Asta A; Visentin S; Sarno L; Xodo S; Bernabini D; Monari F; Roman A; Eke AC; Hoxha A; Ruffatti A; Schuit E; Martinelli P;
    Am J Obstet Gynecol; 2017 May; 216(5):525.e1-525.e12. PubMed ID: 28153662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiphospholipid thrombosis syndrome and acquired activated protein C resistance].
    Wu J; Zhou Z; Li X; Li X; Chen Y; Wang G; Xu X; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2000 Mar; 21(3):122-4. PubMed ID: 11876968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.
    Mondejar R; González-Rodríguez C; Toyos-Sáenz de Miera FJ; Melguizo-Madrid E; Zohoury N; Mahler M; Romero Losquiño I; Fabiani F
    Clin Chim Acta; 2014 Apr; 431():174-8. PubMed ID: 24522162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.